Abstract
The comparative effectiveness of tenofovir (TDF) vs entecavir (ETV) in reducing the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) remains unclear. Data from a retrospective Korean cohort study published by Choi et al(1) initially suggested a lower-than-expected incidence of HCC in patients on long-term TDF. However, additional studies from Korea did not show a statistically significant difference in HCC incidence rate between TDF and ETV groups,(2)(,)(3) and subsequent studies reported mixed results ranging from no association or a slight advantage for TDF.(4) Most of these studies examined Asian patients from Korea, Taiwan, and China.